UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses

Clinical cancer research, 2021-01, Vol.27 (2), p.608-621

2021

Volltextzugriff (PDF)

Prostate Cancer Immunotherapy—Finally in From the Cold?

Current oncology reports, 2021-08, Vol.23 (8), p.88-88, Article 88

2021

Volltextzugriff (PDF)

Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks

Current oncology reports, 2018-09, Vol.20 (9), p.75-10, Article 75

2018

Volltextzugriff (PDF)

Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma

The oncologist (Dayton, Ohio), 2020-02, Vol.25 (2), p.132-139

2020

Volltextzugriff (PDF)

T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer

Clinical cancer research, 2020-07, Vol.26 (13), p.3182-3192

2020

Volltextzugriff (PDF)

Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond

The cancer journal (Sudbury, Mass.), 2018-01, Vol.24 (1), p.20

2018

Volltextzugriff (PDF)

Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer

Cancer cell, 2023-11, Vol.41 (11), p.1972-1988.e5

2023

Volltextzugriff (PDF)

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

Journal for immunotherapy of cancer, 2023-09, Vol.11 (9), p.e006782

2023

Volltextzugriff (PDF)

Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors

Cell reports. Medicine, 2023-01, Vol.4 (1), p.100868, Article 100868

2023

Volltextzugriff (PDF)

Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy

The Prostate, 2020-03, Vol.80 (4), p.336-344

2020

Volltextzugriff (PDF)

Characterization of gene expression and biological pathways in Wilms tumor

Journal of Pediatric Surgery Open, 2023-12, Vol.4, p.100095, Article 100095

2023

Volltextzugriff (PDF)

394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A239-A240

2020

Volltextzugriff (PDF)

The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17089-e17089

2023

Volltextzugriff (PDF)

Abstract PO-046: Single-cell profiling of tumor evolution and complex immune infiltrate induced by ADT and PD-1 blockade in metastatic hormone-sensitive prostate cancer

Cancer research (Chicago, Ill.), 2020-11, Vol.80 (21_Supplement), p.PO-046-PO-046

2020

Volltextzugriff (PDF)

PD24-06 ASSESSMENT OF SURGICAL COMPLICATIONS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC) RECEIVING PERIOPERATIVE CABOZANTINIB AND NIVOLUMAB ON CYTO-KIK CLINICAL TRIAL

The Journal of urology, 2023-04, Vol.209 (Supplement 4)

2023

Volltextzugriff (PDF)

Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.691-691

2023

Volltextzugriff (PDF)

The SPARC-1 trial: A phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS373-TPS373

2021

Volltextzugriff (PDF)

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5115-TPS5115

2022

Volltextzugriff (PDF)

Baseline peripheral T-cell composition in relation to radiographic phenotypes of immune-related pneumonitis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2545-2545

2022

Volltextzugriff (PDF)

Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17503-e17503

2020

Volltextzugriff (PDF)

Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17548-e17548

2020

Volltextzugriff (PDF)

Human prostate cancer immune phenotypes after androgen deprivation therapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5083-5083

2019

Volltextzugriff (PDF)

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS216-TPS216

2022

Volltextzugriff (PDF)

A single-arm phase II study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS271-TPS271

2020

Volltextzugriff (PDF)

A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5082-5082

2022

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses

Prostate Cancer Immunotherapy—Finally in From the Cold?

Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks

Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma

T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer

Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond

Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors

Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy

Characterization of gene expression and biological pathways in Wilms tumor

394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer

Abstract PO-046: Single-cell profiling of tumor evolution and complex immune infiltrate induced by ADT and PD-1 blockade in metastatic hormone-sensitive prostate cancer

PD24-06 ASSESSMENT OF SURGICAL COMPLICATIONS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC) RECEIVING PERIOPERATIVE CABOZANTINIB AND NIVOLUMAB ON CYTO-KIK CLINICAL TRIAL

Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial

The SPARC-1 trial: A phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer

Baseline peripheral T-cell composition in relation to radiographic phenotypes of immune-related pneumonitis

Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer

Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing

Human prostate cancer immune phenotypes after androgen deprivation therapy

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC)

A single-arm phase II study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer

A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8)

Suchergebnisse filtern